Harmony’s Record Quarter Comes with a Measured Second Half

WAKIX revenue hit a new high and beat expectations. Harmony reaffirmed rather than raised its full-year guidance, implying a flatter back half, and disclosed a CFO departure the same day.

Harmony Biosciences (Nasdaq: HRMY) preannounced record second-quarter revenue on Thursday, beat expectations, and reaffirmed its full-year outlook. The more revealing detail is what the company chose not to do: it held its guidance rather than raising it, even after a strong first half.

A Record Quarter

Preliminary net revenue for WAKIX, Harmony’s pitolisant therapy for narcolepsy and its only commercial product, came in at approximately $261 million, a company record. That is up 30% from a year earlier and 21% from the first quarter, and it topped Wall Street expectations, which had clustered around $242 million. The result points to reaccelerating demand after a softer first quarter, which Harmony and analysts have attributed to temporary access and reimbursement friction rather than fading interest in the drug. H.C. Wainwright, which had modeled roughly $220 million for the quarter, read the beat as confirmation that the first-quarter softness reflected access and reimbursement timing rather than weakening demand, and reiterated a Buy rating and $55 price target.

The Guidance Tells the Fuller Story

Harmony reaffirmed full-year revenue guidance of $1.0 billion to $1.04 billion rather than raising it. That is the number worth sitting with. After the first half the company just posted, the range implies second-half revenue of roughly $524 million to $564 million, or a flattening from the sequential jump WAKIX just delivered. There are two honest readings. One is that management is being conservative, leaving room to raise later in the year, a common posture after a strong print. The other is that the first-half strength included timing effects that are not expected to repeat at the same pace. The company has not resolved which it is, and reaffirming rather than raising leaves the question open.

The Concentration Question

The record quarter underscores both Harmony’s strength and its dependence. WAKIX carries the entire commercial business, so the franchise’s durability is the investment case, and its eventual competition and patent life are the risks. That is why the pipeline matters. Harmony is advancing a gastro-resistant formulation of pitolisant and additional central nervous system programs intended to extend the franchise beyond a single product, and it presented new narcolepsy and idiopathic hypersomnia data at a sleep-medicine meeting in June. Progress there is what would diversify a company still defined by one drug.

Separately, Harmony said Chief Financial Officer Glenn Reicin stepped down the same day, with the company’s controller named interim principal financial officer. The company said the departure was not the result of any disagreement over its operations or practices. It is a leadership change to note rather than over-read, and the search for a permanent CFO will play out over the coming months. Harmony reports full second-quarter results and provides a business update on August 4, which should clarify the trajectory behind the reaffirmed guidance.

For informational purposes only. Not investment advice or a recommendation to buy or sell any security. Preliminary results are unaudited, and company forward-looking statements, including revenue guidance, are those of the company and are subject to the risks described in its SEC filings.